GRN-300 is under clinical development by Greenfire Bio and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRN-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRN-300 overview

GRN-300 is under development for the treatment of triple-negative breast cancer. It is administered through oral route. It acts by targeting serine/threonine-protein kinase (SIK2) and serine/threonine-protein kinase (SIK3). The drug candidate is developed based on fragment-field drug design (FFDD) technology platform.
The drug candidate was under development for the treatment of solid tumors, recurrent ovarian cancer, prostate cancer, acute myeloid leukemia (AML), diffuse large B-cell lymphoma and lung cancer, endometrial cancer, primary peritoneal cancer and fallopian tube cancer.

Greenfire Bio overview

Greenfire Bio (Greenfire) is a clinical-stage biopharmaceutical company developing drugs for treating cancer. Its products include GRN-300: ovarian cancer, triple-negative breast cancer, M-001 melanoma, M-002 glioma, M-003 colorectal cancer, M-004 hepatocellular, MGFB: carcinoma, and PCLX-001 refractory colorectal cancer—acute myeloid leukemia (AML). Greenfire operates through its subsidiaries, Green3Bio and MGFB Bio, which focus on developing the SIK2/3 inhibitor and therapeutic vaccine products. The company leverages an integrated ecosystem of development organizations and internal expertise to accelerate product development. Greenfire is headquartered in Austin, Texas, the US.

For a complete picture of GRN-300’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.